Search - tctmd.com

Displaying 481 - 500 of 722

Sort: Relevancy | Date

Presentation TCT 2014

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, John Flack

September 14, 2014

Presentation TCT 2014

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

Presentation TCT 2014

Renal Denervation: Boom or Bust?

Presenter: Martina Kelly Speight, Sarah Clarke, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

Is Renal Denervation a Blockbuster Therapy or Have We Ground to a Halt?

Presenter: Jose Luis Assad-Morell, Efrain Gaxiola, Armando Tellez

September 13, 2014

Presentation TCT 2014

Guidelines and Recommendations for the Practical Application of Renal Denervation Therapies in a Post-SYMPLICITY 3 World

Presenter: Ajay J. Kirtane, Felix Mahfoud, John A. Ormiston, Thomas F. Luscher

September 13, 2014

Presentation TCT 2014

Next Steps: Translational Opportunities and Methodologies to Get Us Back on Track!

Presenter: Juan F. Granada, Paul A. Sobotka, Farrell O. Mendelsohn

September 13, 2014

Presentation TCT 2014

Does One Size Fit All for Renal Denervation to Work? From Symplicity to Complexity

Presenter: Juan F. Granada, Paul A. Sobotka, Farrell O. Mendelsohn, Felix Mahfoud

September 13, 2014

Presentation TCT 2014

TCT 403: Peripheral Endothelial Function and Sympathetic Influence on Dermal Microcirculation Correlate with Long-term Blood Pressure Response in Renal Denervation Patients

Presenter: Juan F. Granada, Paul A. Sobotka, Farrell O. Mendelsohn, Ulrich Hink

September 13, 2014

Presentation TCT 2014

Preclinical Insights Into the Optimal Ablation Location for Renal Denervation Procedures

Presenter: Juan F. Granada, Paul A. Sobotka, Farrell O. Mendelsohn, Robert J. Melder

September 13, 2014

Presentation TCT 2014

TCT 402: Renal Norepinephrine Reduction Following Radiofrequency Renal Denervation Correlates with Extent of Nerve Ablation: Roles of Ablation Areas, Anatomy, and Number of Treatments

Presenter: Juan F. Granada, Paul A. Sobotka, Farrell O. Mendelsohn, Rami Tzafriri

September 13, 2014

Presentation TCT 2014

There Is Hope for Producing Preclinical Models for Successful Device Development

Presenter: Gregory J. Wilson

September 13, 2014

Presentation TCT 2014

Lack of Preclinical Understanding Underlies the Negative Randomized Trial Results!

Presenter: Robert S. Schwartz

September 13, 2014

Presentation TCT 2014

Renal Nerve Microanatomy - The Foundation for RDN Technologies

Presenter: Juan F. Granada, Paul A. Sobotka, Farrell O. Mendelsohn, Michael Joner

September 13, 2014

Presentation TCT 2014

Affirmative: Time to Move On!

Presenter: Sanjay Kaul, Ajay J. Kirtane, Sripal Bangalore

September 13, 2014

Presentation TCT 2014

Negatory: There are Logical Reasons for Why Renal Artery Denervation Failed in SIMPLICITY HTN-3!

Presenter: Sanjay Kaul, Ajay J. Kirtane, David E. Kandzari

September 13, 2014

$SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups$

Presentation TCT 2014

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Presenter: Patrick W. Serruys, Deepak L. Bhatt

September 13, 2014

News Industry News

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

September 13, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

September 13, 2014

News Conference News TCT 2014

Experts Debate Future of Renal Denervation Therapy

September 13, 2014

News Industry News

Medtronic NC Euphora(TM) Coronary Balloon Receives FDA Clearance

September 11, 2014

Advertisement

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Renal Denervation: Boom or Bust?

Is Renal Denervation a Blockbuster Therapy or Have We Ground to a Halt?

Guidelines and Recommendations for the Practical Application of Renal Denervation Therapies in a Post-SYMPLICITY 3 World

Next Steps: Translational Opportunities and Methodologies to Get Us Back on Track!

Does One Size Fit All for Renal Denervation to Work? From Symplicity to Complexity

TCT 403: Peripheral Endothelial Function and Sympathetic Influence on Dermal Microcirculation Correlate with Long-term Blood Pressure Response in Renal Denervation Patients

Preclinical Insights Into the Optimal Ablation Location for Renal Denervation Procedures

TCT 402: Renal Norepinephrine Reduction Following Radiofrequency Renal Denervation Correlates with Extent of Nerve Ablation: Roles of Ablation Areas, Anatomy, and Number of Treatments

There Is Hope for Producing Preclinical Models for Successful Device Development

Lack of Preclinical Understanding Underlies the Negative Randomized Trial Results!

Renal Nerve Microanatomy - The Foundation for RDN Technologies

Affirmative: Time to Move On!

Negatory: There are Logical Reasons for Why Renal Artery Denervation Failed in SIMPLICITY HTN-3!

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Twelve-Month Data from St. Jude Medical EnligHTN Renal Denervation System Show Continued Safety and Efficacy for Patients

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

Experts Debate Future of Renal Denervation Therapy

Medtronic NC Euphora(TM) Coronary Balloon Receives FDA Clearance

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content